These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23808798)

  • 1. Prognostic impact of monocyte count at presentation in mantle cell lymphoma.
    von Hohenstaufen KA; Conconi A; de Campos CP; Franceschetti S; Bertoni F; Margiotta Casaluci G; Stathis A; Ghielmini M; Stussi G; Cavalli F; Gaidano G; Zucca E
    Br J Haematol; 2013 Aug; 162(4):465-73. PubMed ID: 23808798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.
    Hoster E; Klapper W; Hermine O; Kluin-Nelemans HC; Walewski J; van Hoof A; Trneny M; Geisler CH; Di Raimondo F; Szymczyk M; Stilgenbauer S; Thieblemont C; Hallek M; Forstpointner R; Pott C; Ribrag V; Doorduijn J; Hiddemann W; Dreyling MH; Unterhalt M
    J Clin Oncol; 2014 May; 32(13):1338-46. PubMed ID: 24687837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
    Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
    Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absolute monocyte count predicts overall survival in mantle cell lymphomas: correlation with tumour-associated macrophages.
    Koh YW; Shin SJ; Park C; Yoon DH; Suh C; Huh J
    Hematol Oncol; 2014 Dec; 32(4):178-86. PubMed ID: 24910369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.
    Romaguera JE; Fayad LE; Feng L; Hartig K; Weaver P; Rodriguez MA; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Cabanillas F; Kantarjian H; Kwak L; Wang M
    Br J Haematol; 2010 Jul; 150(2):200-8. PubMed ID: 20528872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral blood lymphocyte/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens.
    Li YL; Pan YY; Jiao Y; Ning J; Fan YG; Zhai ZM
    Ann Hematol; 2014 Apr; 93(4):617-26. PubMed ID: 24141331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.
    Merli F; Luminari S; Ilariucci F; Petrini M; Visco C; Ambrosetti A; Stelitano C; Caracciolo F; Di Renzo N; Angrilli F; Carella AM; Capodanno I; Barbolini E; Galimberti S; Federico M
    Br J Haematol; 2012 Feb; 156(3):346-53. PubMed ID: 22145911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic impact of absolute lymphocyte and monocyte counts at diagnosis of diffuse large B-cell lymphoma in the rituximab era.
    Aoki K; Tabata S; Yonetani N; Matsushita A; Ishikawa T
    Acta Haematol; 2013; 130(4):242-6. PubMed ID: 23860478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
    Marcheselli L; Bari A; Anastasia A; Botto B; Puccini B; Dondi A; Carella AM; Alvarez I; Chiarenza A; Arcari A; Salvi F; Federico M
    Br J Haematol; 2015 May; 169(4):544-51. PubMed ID: 25817296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
    Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C
    Am J Hematol; 2013 Dec; 88(12):1062-7. PubMed ID: 23940056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine.
    Inamdar KV; Romaguera JE; Drakos E; Knoblock RJ; Garcia M; Leventaki V; Medeiros LJ; Rassidakis GZ
    Cancer; 2009 Oct; 115(20):4727-36. PubMed ID: 19708031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
    Geisler CH; Kolstad A; Laurell A; Jerkeman M; Räty R; Andersen NS; Pedersen LB; Eriksson M; Nordström M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Brown P; Elonen E;
    Br J Haematol; 2012 Aug; 158(3):355-62. PubMed ID: 22640180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the prognosis of mantle cell lymphoma be predicted by simple CBC counts?
    Haydaroglu Sahin H
    Medicine (Baltimore); 2019 Jul; 98(30):e16180. PubMed ID: 31348229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Watanabe R; Tomita N; Kishimoto K; Koyama S; Ogusa E; Ishii Y; Miyashita K; Matsuura S; Fujisawa S; Hattori Y; Takasaki H; Fujita A; Ohshima R; Kuwabara H; Hashimoto C; Fujimaki K; Sakai R; Ishigatsubo Y
    Leuk Res; 2013 Oct; 37(10):1208-12. PubMed ID: 23927994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the Mantle Cell Lymphoma International Prognostic Index: A single-center retrospective analysis.
    Smith SD; Hsi E; Bolwell B; Pohlman B; Dean R; Effinger M; Maggiotto A; Sweetenham J
    Am J Hematol; 2010 Jun; 85(6):454-6. PubMed ID: 20513126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.
    Garcia M; Romaguera JE; Inamdar KV; Rassidakis GZ; Medeiros LJ
    Cancer; 2009 Mar; 115(5):1041-8. PubMed ID: 19170236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lower peripheral blood lymphocyte/monocyte ratio assessed during routine follow-up after standard first-line chemotherapy is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
    Yan-Li L; Kang-Sheng G; Yue-Yin P; Yang J; Zhi-Min Z
    Leuk Res; 2014 Mar; 38(3):323-8. PubMed ID: 24439567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study.
    Lefrère F; Delmer A; Levy V; Delarue R; Varet B; Hermine O
    Haematologica; 2004 Oct; 89(10):1275-6. PubMed ID: 15477221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.